Bioventus launched its DUROLANE® single-injection hyaluronic acid-based osteoarthritis (OA) treatment in Taiwan, to be marketed by Eulogiums for mild to moderate knee OA.
Bioventus’ orthobiologic products are now available in six countries in the Asia Pacific region.
In 1Q14, Bioventus acquired ex-U.S. DUROLANE assets from Galderma, which still manufactures the product.
Bioventus launched its DUROLANE® single-injection hyaluronic acid-based osteoarthritis (OA) treatment in Taiwan, to be marketed by Eulogiums for mild to moderate knee OA.
Bioventus' orthobiologic products are now available in six countries in the Asia Pacific region.
Source:...
Bioventus launched its DUROLANE® single-injection hyaluronic acid-based osteoarthritis (OA) treatment in Taiwan, to be marketed by Eulogiums for mild to moderate knee OA.
Bioventus’ orthobiologic products are now available in six countries in the Asia Pacific region.
Copy to clipboard 
